Mid-term Results of Chimney and Periscope Grafts in Supra-aortic Branches in High Risk Patients.

PURPOSE: Report mid-term outcomes of thoracic endovascular aneurysm repair (TEVAR) with chimney and periscope grafts (CPG) in supra-aortic branches (SAB). METHODS: Retrospective analysis, from October 2009 to May 2014, of patients with aneurysms requiring TEVAR with zone 0/1/2 proximal landing in association with at least one CPG in the SAB. All patients were considered at high risk for conventional surgery. Peri-operative mortality and morbidity, retrograde type A dissection, maximum aortic transverse diameter (TD) and its post-operative evolution, endoleak, survival, freedom from cardiovascular re-interventions, and CPG freedom from occlusion during the follow-up were analysed. RESULTS: Forty-one patients (28.05% EuroScore II) with thoraco-abdominal aortic aneurysm (17%), arch aneurysm (39%), descending aneurysm (34%), and aneurysm extending from the arch to the visceral aorta (10%) were included. Fifteen (37%) patients were treated non-electively. Fifty-nine SABs were treated with the CPG technique: one, two, three, and four CPG were employed in 71%, 19%, 5%, and 5% of patients, respectively. The proximal landing was in zone 0 in 49% of patients, zone 1 in 17%, and zone 2 in 34%. Technical success was 95%. Peri-operative complications and neurological events were registered in six (14.6%) patients and there were 5 deaths (12%). At a median follow-up of 21.2 (mean 22, SD 18; range 0-65) months, type I/III endoleaks were registered in three (7%) cases and re-intervention in six (15%) patients. A significant aneurysm sac shrinkage (p<.001) was reported at mean follow-up and no significant aneurysm sac increase (>5 mm). The estimated 2 year survival, freedom from re-intervention, freedom from endoleak, and freedom from branch occlusion were 75%, 77%, 86%, and 96%, respectively. CONCLUSION: The chimney and periscope grafts technique was shown to be safe in aortic aneurysm disease involving the supra aortic branches, even in an emergency setting using off the shelf devices. Mid-term follow-up results in this high risk population are good, but longer follow-up is mandatory before this technique is used in intermediate-risk patients.

Experimental murine model of renal cancer. / Modelo murino experimental de cáncer renal.

INTRODUCTION: The objective of this study was to determine the reproducibility in a murine model of renal tumours of various histological strains that could be useful for investigating the response to target drugs. MATERIAL AND METHODS: Development and analysis of the "in vivo" model: tumour xenograft of renal cell carcinomas with Balb/c nude athymic mice. Nontumourous human renal tissue was implanted in the interscapular region of 5 mice, chromophobe renal cell carcinoma was implanted in 5 mice (which, after checking its growth, was prepared for implantation in another 10 mice) and Fuhrman grade 2 clear cell renal cell carcinoma (CCRCC) was implanted in 5 mice (which was also subsequently implanted in 10 mice). We monitored the tumour size, onset of metastases and increase in size and number of tumours. When the size had reached a point greater than or equal to locally advanced or metastatic carcinoma, the animals were euthanised for a pathological and immunohistochemical study and a second phase of implantation. RESULTS: The subcutaneous xenograft of the healthy tissue did not grow. The animals were euthanised at 6 months and no renal tissue was found. The chromophobe renal cell carcinoma cells grew in the initial phase (100%); however, in the second phase, we observed a chronic lymphomonocyte inflammatory reaction and a foreign body reaction. The CCRCC grew at 5-8 months both in the first and second phase (100%), maintaining the tumour type and grade. CONCLUSIONS: The model with athymic Balb/c nude mice is useful for reproducing CCRCC, with the same histological characteristics and aggressiveness as native human tumours, promoting the development of the second experimental phase.

Effect of preoperative oral pravastatin reload in systemic inflammatory response and myocardial damage after coronary artery bypass grafting. A pilot double-blind placebo-controlled study.

AIM: Statins exert pleiotropic effects that result in cardioprotective and antiinflammatory properties. There is a lack of information about the effect of preoperative reloading statin administration in surgical coronary patients regarding myocardial protection, systemic inflammatory response (SIR) attenuation and nitric oxide (NO) metabolism. METHODS: Thirty consecutive dyslipidemic patients under chronic treatment with statins were randomized to orally receive pravastatin 80 mg (N.=10), 40 mg (N.=10) or placebo (N.=10) two hours before anesthetic induction for non-emergent on-pump coronary artery bypass grafting (CABG) procedures. Perioperative peripheral venous and intraoperative CS blood samples were collected for determination of drug-related adverse effects, NO metabolism and both myocardial damage and SIR biomarkers. RESULTS: Pravastatin reloading resulted in a significant and dose-related intense attenuation of SIR, but no differences in cardiac damage biomarker levels were demonstrated. NO release and inducible nitric oxide synthase expression was significantly reduced in both treatment groups. Highest pravastatin doses significantly increased systemic creatine phosphokinase (CPK) concentration compared with intermediate doses but no other adverse effects were observed. CONCLUSION: Oral pravastatin reloading before non-emergent CABG significantly attenuates postoperative SIR and systemic NO/iNOS concentrations with no effect in perioperative myocardial damage. Highest pravastatin doses increase CPK levels and must be avoided in susceptible patients.

Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics.

INTRODUCTION AND HYPOTHESIS: Urinary tract infections (UTIs) are considered the most common bacterial infections, especially in women. The objective of this study was to evaluate the use of the sublingual bacterial vaccine Uromune® in order to prevent recurrent UTIs (RUTIs). METHODS: This study was conceived as a multicenter observational study. The clinical history of 319 women who presented at least 2 episodes of UTI in the last 6 months or 3 in 12 months was reviewed. Data related to treatment and clinical evolution were recorded and analyzed. A total of 159 patients received prophylactic treatment with Uromune® for a period of 3 months (group A) and 160 with sulfamethoxazole/trimethoprim 200/40 mg/day for a period of 6 months (group B). Uromune® contained an inactivated bacterial cell suspension of selected strains of Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris, and Enterococcus faecalis. RESULTS: Patients in group A experienced a highly significant reduction in the number of infections compared to patients in group B. In the first 3 months, the mean number of infections was 0.36 versus 1.60 (P < 0.0001), respectively. A significant reduction was also observed after 9 and 15 months (P < 0.0001). The numbers of patients who did not have any UTI at 3, 9, and 15 months were 101, 90, and 55 in group A versus 9, 4, and 0 in group B (P < 0.0001). CONCLUSIONS: The results obtained in this study favor the use of this bacterial-based therapeutic vaccine as an effective strategy to reduce frequency, duration, severity, and costs of RUTIs.

Effects and mechanism of organ protection by cardiotrophin-1.

Cardiotrophin-1 (CT-1), a member of the interleukin (IL)-6 family, is reported to exhibit a plethora of pleiotropic effects in the heart such as cytoprotective, pro-proliferative and pro-fibrotic ones. An extensive research has been devoted on proliferative and profibrotic effects of CT-1 on the heart. Thus the present review has been aimed to critically define the cytoprotective effects of CT-1 and the cellular and molecular mechanisms involved in them. Although many effects of CT-1 have been described on the heart, CT-1 has now also been reported to exhibit important protective effects in other organs such as liver, kidney or nervous system. CT-1 produces its effects through a unique receptor system comprising LIF receptor (LIFRß) and a common signal transducer, the glycoprotein 130 (gp130). The signaling pathway downstream from gp130 is based on at least, three distinct pathways: 1) the janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway, 2) the p42/44 mitogen-activated protein kinase (p42/44 MAPK) pathway, also known as the extracellular receptor kinase-1/2 (ERK1/2) pathway, and 3) the phosphatidylinositol 3-OH kinase (PI3K)/Akt pathway. Since CT-1 easily achieves its cytoprotective effects via a combination of the above three signaling pathways, it becomes quite necessary to determine which pathway(s) is involved in each particular effect of CT-1. In each of its target organs, CT-1 may also display differential mechanisms of cytoprotection, and thus it is relevant to understand how these mechanisms are locally regulated.

Técnicas y estrategias durante la reparación endovascular de la aorta torácica / Aortic-Branch management during tevar: Techniques and strategies

Thoracic endovascular aortic repair (TEVAR) is rapidly becoming the preferred form of intervention for treatment of a large proportion of patients presenting with life-threatening diseases affecting the thoracic aorta, such as aneurysms, dissection, and traumatic injuries. El autor analizalasdiferentes opciones en el tratamiento de la patología de la aorta torácica (AU)

Thoracic endovascular aortic repair (TEVAR) is rapidly becoming the preferred form of intervention for treatment of a large proportion of patients presenting with life-threatening diseases affecting the thoracic aorta, such as aneurysms, dissection, and traumatic injuries. The author analyze the different possibilities in the treatment of thoracic aorta pathology (AU)

Clinical profile and epidemiological changes of clear cell renal carcinoma during 12 years in our health area.

OBJECTIVES: To investigate changes in the epidemiology and clinical profile of patients diagnosed with renal clear cell carcinoma in a community health area over 12 years. METHODS: Retrospective analysis of epidemiological characteristics and clinical profile of patients diagnosed with renal clear cell carcinoma in a health area composed of a population of 353.619 inhabitants from January 1999 to December 2010. Descriptive statistical and multivariate analysis, Fisher exact test and Chi-Square were utilized. p<0.05 was accepted as significant. RESULTS: 349 diagnoses of renal mass were reported; 165 of them were clear renal cell carcinoma. Median age was 70.41 years, and the Female/Male rate was 28% and 72%, respectively. 4% women and 30% men smoked ≥20 cigarettes/day, more frequently during the period 1999-2001. 52% women and 30% men had hypertension. Hematuria was the most frequent symptom (23%), more frequent in the period 2007-2010, followed by abdominal pain (16%) and renal colic(13%). Weight loss (12%) was more frequent between 1999-2000. Asthenia appeared as the first symptom in 8% of cases. The tumor was incidentally diagnosed in 20% of cases, more frequently in the period between 2007-2010. Diagnosis was established in the Urology Department in 36% of the cases. Stages T1-2 N0 were more frequent between 2007-2010, and M1 between 1999-2000. G3 was more frequent in the entire series. The relative cancer specific mortality of patients who were surgically treated was less in the last 2 years of the period. CONCLUSIONS: Clear renal cell carcinoma is the most frequent renal cancer and its incidence is increasing in our environment. It affects more frequently males than females, and at an earlier age. The last few years are showing a decrease in the habitual smoker males and an increase in HTN in females. A tendency has been detected to the early stage clinical diagnosis but with a higher histopathological grade. It is most frequent diagnosed by a non-Urology speciality.

Perfil clínico y cambios epidemiológicos del carcinoma renal de células claras a lo largo de 12 años en un área de salud / Clinical profile and epidemiological changes of clear cell renal carcinoma during 12 years in our health area

OBJETIVO: Investigar si se producen cambios en la epidemiología y en el perfil clínico de los pacientes diagnosticados de carcinoma renal de células claras (CRCC) en un área de salud a lo largo de 12 años. MÉTODOS: Se realiza un análisis retrospectivo de las características epidemiológicas y del perfil clínico (sexo, edad, factores de riesgo, estadio tumoral y supervivencia) de los pacientes diagnosticados de CRCC en un área de salud de 353619 habitantes desde enero de 1999 hasta diciembre de 2010. Se utiliza estadística descriptiva, t de Student, test exacto de Fisher y Chi-Square. p<0.05 se aceptó como significativo(AU)

RESULTADOS: Se emitieron 349 diagnósticos de masa renal, de los cuales 165 casos corresponden a CRCC. La edad media fue de 70.41 años, y la distribución mujeres/varones fue 28/72%. El consumo de ≥20 cigarillos/día se presentó en el 4% de las mujeres y en el 30% de los hombres, siendo más frecuente en 1999-2001. El 52% de las mujeres y el 30 % de los hombres padecían hipertensión arterial (HTA). La hematuria fue el síntoma más frecuente, apareciendo en un 23%, más frecuente en 2007-2010 (p<0.034). Los siguientes síntomas en frecuencia fueron el dolor abdominal (16%) y las crisis renoureterales (13%). La pérdida de peso (12%) fue más frecuente entre los años 1999 y 2000. La astenia apareció como síntoma primero en un 8% de casos. El diagnóstico fue incidental en un 20% de los casos, más frecuente entre los años 2007 y 2010 (p<0.0081).Conocido tradicionalmente como el tumor del internista, corroboramos que solo el 36% de estos tumores fueron diagnosticados en Urología y el 64% en otras especialidades. En cuanto al estadio, T1-T2 y N0 fueron más frecuentes en los últimos 4 años respecto a 1999-2006 (p<0.016 y p<0.0002 respectivamente). M1 fue más frecuente que M0 en 1999-2000 (p<0.0021) y M0 más frecuente en 2004-2010 (p<0.0038). G3 fue más frecuente en toda la serie, más acentuado en 2008-2010 (p<0.0186). La mortalidad relativa cáncer-específica de los pacientes tratados quirúrgicamente fue menor en los dos últimos años del periodo (p<0.0314). CONCLUSIONES: El CRCC es el cáncer renal más frecuente y con incidencia en aumento en nuestro medio. Afecta más y a menor edad a hombres que a mujeres. En los últimos años se registra menos tabaquismo severo en hombres y más HTA en mujeres. Existe una tendencia al diagnóstico en estadio clínico más precoz pero con mayor grado histopatológico. El diagnóstico se realiza con mayor frecuencia en especialidad no urológica(AU)

OBJECTIVES: To investigate changes in the epidemiology and clinical profile of patients diagnosed with renal clear cell carcinoma in a community health area over 12 years. METHODS: Retrospective analysis of epidemiological characteristics and clinical profile of patients diagnosed with renal clear cell carcinoma in a health area composed of a population of 353.619 inhabitants from January 1999 to December 2010. Descriptive statistical and multivariate analysis, Fisher exact test and Chi-Square were utilized. p<0.05 was accepted as significant. RESULTS: 349 diagnoses of renal mass were reported; 165 of them were clear renal cell carcinoma. Median age was 70.41 years, and the Female/Male rate was 28% and 72%, respectively. 4% women and 30% men smoked ≥20cigarettes/day, more frequently during the period 1999-2001. 52% women and 30% men had hypertension. Hematuria was the most frequent symptom (23%), more frequent in the period 2007-2010, followed by abdominal pain (16%) and renal colic (13%). Weight loss (12%) was more frequent between 1999-2000. Asthenia appeared as the first symptom in 8% of cases. The tumor was incidentally diagnosed in 20% of cases, more frequently in the period between 2007-2010.Diagnosis was established in the Urology Department in 36% of the cases. Stages T1-2 N0 were more frequent between 2007-2010, and M1 between 1999-2000. G3 was more frequent in the entire series. The relative cancer specific mortality of patients who were surgically treated was less in the last 2 years of the period(AU)

CONCLUSIONS: Clear renal cell carcinoma is the most frequent renal cancer and its incidence is increasing in our environment. It affects more frequently males than females, and at an earlier age. The last few years are showing a decrease in the habitual smoker males and an increase in HTN in females. A tendency has been detected to the early stage clinical diagnosis but with a higher histopathological grade. It is most frequent diagnosed by a non-Urology speciality(AU)

Factores de riesgo de fracaso de la corrección quirúrgica de la incontinencia urinaria de esfuerzo mediante cinta suburetral transobturatriz / Risk Factors for Failure After Transobturator Vaginal Tape for Urinary Incontinence

Objetivos: Identificar factores que llevaron al fracaso del tratamiento quirúrgico en 302 mujeres con incontinencia urinaria de esfuerzo (IUE) tratadas mediante cinta suburetral transobturatriz (TOT) con seguimiento de 4 años (rango 1-6).Material y métodos302 mujeres incontinentes de 41-81 años fueron intervenidas mediante TOT entre abril de 2003 y noviembre de 2010. Los datos se recogieron mediante el cuestionario validado para incontinencia de orina, el International Consultation on Incontinence Questionnaire — Short Form (ICIQ-SF), y los registros clínicos de la historia. En 262 se consiguió continencia (grupo A) y 40 siguieron incontinentes (grupo B). Se investigó: edad, tiempo de evolución de IUE, tipo y número de partos (eutócicos, distócicos, nuliparidad, multiparidad) y antecedentes médicos y/ o quirúrgicos. Se empleó el cuestionario ICIQ-SF para asignar si los resultados de la cirugía fueron o no exitosos. Resultados: El grupo A presentó menor edad (p=0,0001), menos tiempo de evolución de IUE (p=0,017) y más partos eutócicos (p=0,00002). El grupo B presentó más partos distócicos (p=0,002), colocación previa de cinta vaginal libre de tensión (TVT) o TOT (p=0,03), tratamiento antidepresivo-ansiolítico (p=0,003), tratamiento antihipertensivo (p=0,0005), DMID (p=0.02), HTA (p=0,0007), trastornos respiratorios (p=0,025). No hubo diferencia en nuliparidad (p=0,7), multiparidad (p=0,4), obesidad (p=0,18), trastornos intestinales (p=0,59), anexectomía (p=0,19), cesárea (p=0,17), colposuspensión (p=0,29), histerectomía (p=0,57), alergias (p=0,48), artritis (p=0,22), artrosis (p=0,44), depresión (p=0,74), DMNID (p=0,44), tabaquismo (p=0,28) o fibromialgia (p=0,47). Conclusiones: Edad avanzada, largo tiempo de evolución de la incontinencia urinaria, antecedentes de partos distócicos y la colocación de TVT o TOT previamente aparecen como los factores independientes más asociados al fracaso del TOT, y pueden hacer aconsejable la indicación de otra técnica quirúrgica (AU)

Objective: To identify risk factors leading to treatment failure in a sample of 302 women with stress urinary incontinence (SUI) treated by transobturator vaginal tape (TOT) with a medium follow-up of 4 years (range 1-6). Material and Methods: A population based cohort study with prospectively data from 302 women, aged 41-81 years underwent TOT between April 2003-November 2010. Data were collected by validated questionnaire on urinary incontinence, the International Consultation on Incontinence Questionnaire — Short Form (ICIQ-SF), and clinical data-records. Continence was achieved in 262 (Group A) and 40 continued with incontinence (Group B). We investigated the relationship between age, SUI evolution time, type and number of childbirths (eutocic, dystocic, nulliparous, multiparous status) and medical and/or surgical backgrounds. The ICIQ-SF questionnaire was used to describe whether the surgery outcomes were successful or not. Results: Group A were younger (p=0.0001), had less SUI evolution time (p=0.017); more eutocic childbirths (p=0.000018). Group B had more dystocic childbirth (p=0.022), previous tension free vaginal tape (TVT) or TOT (p=0.03.), antidepressant-anxiolytic drugs (p=0.003), antihypertensive drugs (p=0.0005), type 1 diabetes (p=0.02), arterial hypertension (p=0.0007), respiratory diseases (p=0.025). Differences were not found with regard to nulliparous (p=0.701), multiparous status (p=0.42), obesity (p=0.18), intestinal disorders (p=0.59), oophorectomy (p=0.19), caesarean (p=0.17), prolapse surgery (p=0.29), hysterectomy (p=0.57), allergies (p=0.48), arthritis (p=0.22), arthrosis (p=0.44), depression (p=0.74), type 2 diabetes (p=0.44), smoking patterns (p=0.28), fibromyalgia (p=0.47). Conclusions: Elderly women, with long evolution SUI, dystocic delivery, previous TVT or TOT appear as independent risk factors associated to TOT failure. These factors may make the indication of another surgical approach recommendable (AU)

[Risk factors for failure after transobturator vaginal tape for urinary incontinence]. / Factores de riesgo de fracaso de la corrección quirúrgica de la incontinencia urinaria de esfuerzo mediante cinta suburetral transobturatriz.

OBJECTIVE: To identify risk factors leading to treatment failure in a sample of 302 women with stress urinary incontinence (SUI) treated by transobturator vaginal tape (TOT) with a medium follow-up of 4 years (range 1-6). MATERIAL AND METHODS: A population based cohort study with prospectively data from 302 women, aged 41-81 years underwent TOT between April 2003-November 2010. Data were collected by validated questionnaire on urinary incontinence, the International Consultation on Incontinence Questionnaire - Short Form (ICIQ-SF), and clinical data-records. Continence was achieved in 262 (Group A) and 40 continued with incontinence (Group B). We investigated the relationship between age, SUI evolution time, type and number of childbirths (eutocic, dystocic, nulliparous, multiparous status) and medical and/or surgical backgrounds. The ICIQ-SF questionnaire was used to describe whether the surgery outcomes were successful or not. RESULTS: Group A were younger (p=0.0001), had less SUI evolution time (p=0.017); more eutocic childbirths (p=0.000018). Group B had more dystocic childbirth (p=0.022), previous tension free vaginal tape (TVT) or TOT (p=0.03.), antidepressant-anxiolytic drugs (p=0.003), antihypertensive drugs (p=0.0005), type 1 diabetes (p=0.02), arterial hypertension (p=0.0007), respiratory diseases (p=0.025). Differences were not found with regard to nulliparous (p=0.701), multiparous status (p=0.42), obesity (p=0.18), intestinal disorders (p=0.59), oophorectomy (p=0.19), caesarean (p=0.17), prolapse surgery (p=0.29), hysterectomy (p=0.57), allergies (p=0.48), arthritis (p=0.22), arthrosis (p=0.44), depression (p=0.74), type 2 diabetes (p=0.44), smoking patterns (p=0.28), fibromyalgia (p=0.47). CONCLUSIONS: Elderly women, with long evolution SUI, dystocic delivery, previous TVT or TOT appear as independent risk factors associated to TOT failure. These factors may make the indication of another surgical approach recommendable.

Fisioterapia y personas con discapacidad: papel de la fisioterapia coadyuvante en la discapacidad física y psicosomática causada por la cistopatía intersticial / Physiotherapy and persons with disability: role of coadjuvant physiotherapy in the physical and psychosomatic disability caused by interstitial cystitis

La cistopatía intersticial es un síndrome clínico caracterizado por frecuencia urinaria y/o dolor pelviano de etiología no establecida que excluye otras causas conocidas. Su escaso conocimiento en el ámbito clínico y, en especial, en su repercusión biopsicosocial incentiva hoy en día la realización de estudios específicos entre los que éste aporta una visión terapéutica efectiva mediante biofeedback de suelo pelviano sin electroestimulación partiendo de un protocolo básico de la Asociación Europea de Urología, aplicado a pacientes diagnosticadas de cistopatía intersticial, para producir una mejora en la calidad de vida y una reducción de la discapacidad o de la invalidez temporal en relación con el síndrome(AU)

Interstitial cystitis is a clinical syndrome characterized by urinary frequency and/or pelvic pain with a non-established etiology that excludes any other known causes. The limited knowledge within the clinical fields and especially about its biopsychosocial effects currently encourages the conduction of specific studies. Among these, there are those that provide an effective therapeutic view using pelvic floor biofeedback without electrostimulation, using a basic protocol of the Urology European Association, applied to interstitial cystitis diagnosed patients, that aims to generate an improvement in their quality of life and of reducing the disability or the temporary impairment related to the syndrome(AU)

[Treatment of stress urinary incontinence with perineal biofeedback by using superficial electrodes]. / Tratamiento de la incontinencia urinaria de esfuerzo con biofeedback perineal con electrodos de superficie.

PURPOSE: We analyze the pelvic floor muscles treatment outcomes by using biofeedback (BFB) with electromyography with superficial electrodes in women diagnosed as having stress urinary incontinence (SUI). Besides, we compare this treatment with pelvic floor muscle exercises (PFME) plus vaginal electrostimulation. METHODS: 85 women with stress urinary incontinence, aged 42 - 74 years. We divided the patients in two groups: Group 1 (N = 50): This patients carry out a perineal biofeedback with superficial electrodes without electrostimulation, and Group 2 (N = 35): This patients were treated with pelvis floor muscle exercices and vaginal electrostimulation. All patients carry out two session per week (of 30 minutes each one) during ten weeks. We assess the outcomes through international urinary incontinence questionnaires (IU-5 and ICIQ-SF) and urinary incontinence related quality of life test (King's questionnaire). Student t-test and Fisher Exact test were used, p < 0.05 was considered statistically significant. RESULTS: No difference was found in the age average of both groups. 84% of patients of group 1 and 80% of patients of group 2 were cured with the treatment. We assumed they were cured when incontinence episodes not happened or they do not need to use absorbent materials. In the Group 1, 50% of patients in the fourth week and 84% in the tenth week were cured. In the Group 2, 71.42% of patients in the fourth week and 80% in the tenth week were cured. In the Group 2, eight patients (22.85%) complained side effects. Both groups improved the quality of life similarly. CONCLUSION: Grade 1 and grade 2 stress urinary incontinence treatment by using perineal biofeedback with superficial electrodes electromyography is better or similar to more invasive treatments. Also pelvic floor muscle exercices plus vaginal electrostimulation have good outcomes although some patients complain side effects. Both conservative treatments are effective and feasible.

Tratamiento de la incontinencia urinaria de esfuerzo con Biofeedback perineal con electrodos de superficie / Treatment of stress urinary incontinence with perineal biofeedback by using superficial electrodes

Objetivo: Se analiza el resultado del tratamiento de los músculos perineales mediante biofeedback (BFB) con electrodos de superficie en mujeres diagnosticadas de incontinencia urinaria de esfuerzo (IUE). Además se compara con la reeducación de la musculatura del suelo pélvico (RMSP) más electroestimulación vaginal (EEV). Métodos: 85 mujeres diagnosticadas de IUE; de edades comprendidas entre 42 y 74 años, se dividieron en: Grupo 1 (N=50): tratadas mediante un programa de BFB perineal con electrodos de superficie sin electroestimulación y Grupo 2 (N=35): tratadas con RMSP con EEV. Se realizaron dos sesiones semanales de 30 minutos cada una durante 10 semanas. Se evaluaron los resultados mediante el estudio de los cambios en los índices internacionales de la incontinencia urinaria (IU–5 y el índice ICIQ-SF) y el índice de calidad de vida derivada de los síntomas urinarios (cuestionario de salud King´s). Se emplearon la t de Student y el test exacto de Fisher, p < 0,05 se aceptó como significación estadística. Resultados: La edad de ambos grupos fue comparable. 84% y 80% de pacientes en los grupos 1 y 2 mejoraron respectivamente, entendiendo por mejora la no existencia de episodios de incontinencia y la ausencia de necesidad de usar absorbentes. No hubo diferencia en la mejora de la incontinencia entre ambos grupos. En el Grupo 1 la mejora se produjo en el 50% de pacientes en la semana 4, y en el 84%en la semana 10. En el Grupo 2 la mejoría ocurrió en el 71,42% de pacientes en la semana 4 y en el 80% de pacientes en la semana 10.Ocho pacientes del Grupo 2 (22,85%) presentaron efectos secundarios locales. La mejora en la calidad de vida en ambos grupos arrojó resultados similares. Conclusión: El éxito del tratamiento de la incontinencia urinaria de esfuerzo grados 1 y 2 mediante un programa de biofeedback perineal con electromiografía con electrodos de superficie sin electroestimulación es similar o superior a los publicados en tratamientos más invasivos. El tratamiento con ejercicios del suelo pélvico con electroestimulación vaginal puede conseguir resultados similares, aunque puede presentar efectos secundarios. Ambos tratamientos conservadores son eficaces y factibles (AU)

Purpose: We analyze the pelvic floor muscles treatment outcomes by using biofeedback (BFB) with electromyography with superficial electrodes in women diagnosed as having stress urinary incontinence (SUI). Besides, we compare this treatment with pelvic floor muscle exercises (PFME) plus vaginal electrostimulation. Methods: 85 women with stress urinary incontinence, aged 42 - 74 years. We divided the patients in two groups: Group 1 (N=50): This patients carry out a perineal biofeedback with superficial electrodes without electrostimulation, and Group 2 (N=35): This patients were treated with pelvis floor muscle exercices and vaginal electrostimulation. All patients carry out two session per week (of 30 minutes each one) during ten weeks. We assess the outcomes through international urinary incontinence questionnaires (IU–5 and ICIQ-SF) and urinary incontinence related quality of life test (King´s questionnaire). Student t-test and Fisher Exact test were used, p < 0.05 was considered statistically significant. Results: No difference was found in the age average of both groups. 84% of patients of group 1 and 80% of patients of group 2 we recured with the treatment. We assumed they were cured when incontinence episodes not happened or they do not need to use absorbent materials. In the Group 1, 50% of patients in the fourth week and 84% in the tenth week were cured. In the Group 2, 71,42% of patients in the fourth week and 80% in the tenth week were cured. In the Group 2, eight patients (22,85%) complained side effects. Both groups improved the quality of life similarly. Conclusion: Grade 1 and grade 2 stress urinary incontinence treatment by using perineal biofeedback with superficial electrodes electromyography is better or similar to more invasive treatments. Also pelvic floor muscle exercices plus vaginal electrostimulation have good outcomes although some patients complain side effects. Both conservative treatments are effective and feasible (AU)

Study of the efficacy of Coated VICRYL Plus Antibacterial suture (coated Polyglactin 910 suture with Triclosan) in two animal models of general surgery.

OBJECTIVES: To evaluate the efficacy in vitro and in vivo of a new antibacterial suture (PGAB) compared with a traditional braided suture (PG). Our primary goals were to study microbiological effectiveness and impact on wound healing of PGAB vs PG. Secondary goal was to analyze influence on inflammatory response. METHODS: In vitro study: clinical samples of Staphylococcus epidermidis, Staphylococcus aureus, S. hominis, Staphylococcus haemolyticus, Staphylococcus auricularis, Enterococcus faecalis, Corynebacterium spp. and Escherichia coli were studied. We also implanted a flat mesh in 10 minipigs, four incisions each (two PG and two PGAB) two contaminated with S. epidermidis and two not contaminated. Finally, we performed four colic anastomosis in each of 10 minipigs, two contaminated with E. coli and two not contaminated (two PG and two PGAB). We studied the inflammatory and wound healing processes in both models. RESULTS: We observed a bactericidal efficacy of PGAB against grampositive, and bacteriostatic effect against E. coli. Mesh study: recovered CFU were lower in the group PGAB vs PG. In the group PGAB, inflammatory mediators' concentrations were lower. In the group PGAB, concentrations of wound healing mediators were normal. Colic anastomosis: recovered CFU were lower in the group PGAB vs the group PG. In the group PGAB we observed a reduction of inflammatory mediators. In the group PGAB we observed normalized concentrations of wound healing mediators. CONCLUSIONS: This study demonstrates microbiological efficacy of PGAB, that normalizes wound healing process, and an anti-inflammatory effect.

Estudio de farmacovigilancia para evaluar la seguridad y la efectividad del tratamiento con losartán: efectos a largo plazo de losartán solo o en combinación sobre la uricemia / Pharmacovigilance study of the safety and effectiveness of losartan therapy: long-term effects of losartan alone or in combination on uricemia

Introducción: se evalúa la acción del tratamiento con losartán sobre la uricemia, en pacientes hipertensos en el medio comunitario. Material y método: estudio de farmacovigilancia, observacional, prospectivo, multicéntrico, no aleatorizado, abierto, de 1 año de seguimiento. Centros de atención primaria de Ávila, Burgos, León, Palencia, Salamanca, Valladolid y Zamora. Se incluyó a 275 pacientes de 67,5 años, con hipertensión arterial, no diabéticos y diabéticos (n = 19), a los que se trató con losartán, 50 mg/día. A las 8 semanas se aumentaba a 100 mg/día si era preciso. Si a las 24 semanas la presión arterial (PA) persistía elevada, se añadía hidroclorotiazida, 25 mg. Se procedió a la toma de sangre para uricemia, creatinina, electrolitos, glucemia, colesterol y triglicéridos al comienzo y a las 48 semanas de tratamiento. Resultados: la uricemia disminuyó significativamente en el grupo de pacientes tratados con losartán y losartán + tiazidas. El 30% de los pacientes recibió 50 mg de losartán, el 14%, 100 mg y el 56%, losartán + tiazida. La PA media ± desviación estándar varió desde 166 ± 29 mmHg de sistólica y 96 ± 19 mmHg, al comienzo del estudio, a 145 ± 23 mmHg de sistólica y 83 ± 18 mmHg de diastólica al finalizarlo. La creatinina, el sodio, el potasio, la glucemia, el colesterol y los triglicéridos no sufrieron deterioro durante el año de seguimiento. Conclusiones: el losartán es un fármaco seguro, con pocos efectos secundarios y que, tras 1 año de seguimiento, disminuye la uricemia sin deterioro del perfil lipídico, hidrocarbonato ni renal. Se postula como fármaco de primera elección en hipertensos mayores con hiperuricemia

Objectives: to evaluate the effect of losartan therapy on uricemia in patients with hypertension in the community setting. Design: observational, prospective, multicenter, nonrandomized, open-label pharmacovigilance study with a 1-year follow-up. Setting: primary care centers in Avila, Burgos, Leon, Palencia, Salamanca, Valladolid, and Zamora (Spain). Patients and method: two hundred seventy-five men and women (mean age 67.5 years), without diabetes (n = 256) and with diabetes (n = 19), treated with 50 mg/day of losartan were included. If high blood pressure (BP) (> 140/90 mmHg) was uncontrolled at 8 weeks, the dose was increased to 100 mg/day. If BP continued to be high at 24 weeks, hydrochlorothiazide (25 mg) was added. BP was measured after the patient had been sitting for 7 minutes with a mercury manometer and phase V Korotkoff's sound as the reference point. Blood samples were drawn for analysis of uricemia, creatinine, electrolytes, glycemia, cholesterol, and triglycerides at the beginning of the study and after 48 weeks' treatment. Results: uricemia significantly decreased in the group of patients treated with losartan and losartan + thiazides. Thirty percent of the patients received 50 mg of losartan, 14% received 100 mg and 56% received losartan + thiazide. Systolic BP was reduced from 166 (SD 29) mmHg at the beginning of the study to 145 (SD 23) at the end of the study. Diastolic BP was reduced from 96 (SD 19) mmHg to 83 (SD 18) mmHg. No negative effects on creatinine, sodium, potassium, glycemia, cholesterol or triglyceride values were found during the 1-year follow-up. Conclusions: losartan is a safe drug with few adverse effects. After a 1-year follow-up, it reduces uricemia without producing negative effects on lipid, carbohydrate or renal profiles. Therefore, it could be used as a first-line drug in elderly patients with hypertension and hyperuricemia

Nitric oxide prevents the bacterial translocation and inhibits the systemic inflammatory response produced by implantation of a vascular prosthesis followed by Zymosan A.

OBJECTIVE AND DESIGN: To evaluate the beneficial effects of exogenous NO and its levels of action in a model of SIRS/Bacterial Translocation (BT) induced by two sequential insults. MATERIAL OR SUBJECTS: Eighty-six Wistar rats were submitted to different treatments and their tissue and blood samples were accessed at the end of the experiment. TREATMENT: Nitric Oxide was compared to Gentamicin as the tested guideline for our study. METHODS: Dacron graft implantation (first insult) and subsequent administration of Zymosan A((R)) (second insult) were performed in Wistar rats. The animals were divided into 6 groups: I) No manipulation (BASAL: ); II) Laparotomy (L) + mineral oil (SHAM: ); III) L + Graft-Zymosan (GZ) (CONTROL: ); IV) L + GZ + Antibiotic (A) (ASSAY: I); V) L + GZ + NO (ASSAY: II) and VI) L + GZ + A + NO (ASSAY: III). Determinations: Survival, Bacterial Translocation, myeloperoxidase (MPO), Cytokines (TNF-alpha, IL-1beta, IFN-gamma), Oxygen Free Radical (OFR) SOA and detoxifying enzymes (SOD, Superoxide Dismutase, CAT, Catalase and GPX, Glutathione Peroxidase), Cell Adhesion Molecules, CAMs (ICAM-1, VCAM-1 and PECAM-1) and Nuclear Transcription Factor, NFkappaB. RESULTS: The model established induced a mortality rate of 20% and generated BT in all samples. It also significantly increased all variables, with P < 0.001 for MPO and all Cytokines; P < 0.01 for all OFR, and P < 0.05 for CAMs and for NFkappaB. Treatment with A reduced mortality to 0%, significantly decreased BT, MPO, Cytokines and OFR (P < 0.05), but did not reduce CAMs or NFkappaB. NO, either alone or associated, reduced mortality to 0% and abolished BT, significantly decreasing nearly all the variables studied (P < 0.001 for MPO and all Cytokines; P < 0.01 for OFR, and P < 0.05 for CAMs and for NFkappaB). CONCLUSIONS: The exogenous administration of NO before the two sequential insults prevented BT and controlled SIRS peripherally and at both cellular and transcriptional level in a lasting manner. In contrast, antibiotic treatment only exerted its action at peripheral level. The association of both treatments did not provide any important advantages.

Endograft repair of acute aortic dissection. Promises and challenges.

Acute dissection is a uniquely complex, relatively common, and frequently lethal aortic catastrophe. Historically, surgical treatment has been reserved for cases with complications including rupture; the results have been less than optimal because of excessive morbidity and mortality. This is the main reason why conservative management emerged as the standard of care for management of acute type B aortic dissection (TBAD). While more patients would appear to survive with a conservative treatment strategy, the outcome in terms of 30-day mortality (20%) and occurrence of late complications - such as enlarging aneurysms of the thoracic false lumen (30-40%) - leaves (again) much to be desired. Stent-graft endovascular repair has emerged as a very promising, less invasive treatment option. These devices, when used appropriately, can achieve the important therapeutic goals of entry-site coverage, depressurization of the false lumen, and expansion of the compressed true lumen - overcoming ischemic (malperfusion) manifestations. The early results of stent-graft repair of TBAD are encouraging, and even exciting, but much more work needs to be done in various critical areas surrounding this condition. Thoracic endograft technology has lagged behind its abdominal counterpart. The design of acute dissection-specific devices is imperative, reflecting the significant differences between TBAD and degenerative thoracic aortic aneurysm disease. Needs for this and other important developments notwithstanding, it is generally acknowledged that stent-graft intervention does represent an important advance in the treatment of patients with TBAD. Well-designed, controlled clinical trials will be necessary to elucidate the relative value of several endovascular thoracic strategies.

Consecuencias del precondicionamiento sobre los efectos de la isquemia intestinal en un modelo experimental en ratas / Consequences of preconditioning on the effects of intestinal ischemia in a rat experimental model

Introducción. El precondicionamiento isquémico se define como el efecto protector frente a la isquemia de larga duración experimentado por un órgano si previamente ha sido sometido a cortos períodos de isquemia. El fenómeno no es bien conocido y su duración y el grado de protección que proporciona varía según el tipo de tejido y modelo experimental utilizado. El objetivo de la presente publicación es estudiar el efecto del precondicionamiento en un modelo de isquemia/reperfusión intestinal en la rata evaluando los valores de superóxido dismutasa (SOD), principal enzima detoxificante, frente a los radicales libres del oxígeno, la lesión histológica y la mortalidad.Material y métodos. Se han utilizado ratas adultas, aleatoriamente asignadas a tres grupos: grupo simulado, grupo control en el que se provocó isquemia intestinal y grupo de estudio en el que, antes de la isquemia, los animales fueron sometidos a precondicionamiento. La isquemia se realizó por pinzamiento de la arteria mesentérica en su origen durante 90 min. El precondicionamiento consistió en 5 min de isquemia seguidos de 10 min de reperfusión previos a la isquemia de 90 min. Estudiamos la supervivencia a las 24 y 72 h, los niveles de SOD en la pared intestinal y los cambios morfológicos de la mucosa intestinal.Resultados. En los animales sometidos a precondicionamiento, se evidencian mayores valores de SOD y un incremento de la supervivencia con respecto a los grupos sin precondicionamiento, tanto a las 24 h (el 84 frente al 73 por ciento) como a las 72 h (el 83 frente al 53 por ciento) aunque estas diferencias no resultan significativas. El estudio histológico objetiva un menor grado de lesión de la pared intestinal en los animales sometidos a precondicionamiento (predominio de lesiones de los grados I y II de Chiu).Conclusiones. La realización de cortos períodos de isquemia intestinal provoca aumento de la resistencia del intestino a isquemias posteriores de mayor duración. Este efecto beneficioso se objetiva por un incremento de la supervivencia y un menor grado de lesión histológica del intestino, y se asocia con valores significativamente más elevados de SOD en la pared intestinal. (AU)